eps

Cisco Systems Stock Down After Earnings

Cisco Systems Stock Down After Earnings

Cisco Systems, Inc. (NASDAQ: CSCO) announced Q4 and FY2017 results after the bell yesterday, culminating in a 4% drop in stock price today.The company met revenue expectations as well as estimates for earnings per share again, however it also report..

Wal-Mart Stores, Inc. Reported its Second Quarter, Shares Down

Wal-Mart Stores, Inc. Reported its Second Quarter, Shares Down

Wal-Mart Stores, Inc. (NYSE: WMT) reported its second quarter earnings for the 2018 fiscal year and beat estimates. Shares were down almost 3 percent during pre-market.Wal-Mart posted adjusted earnings of $1.08 compared to an estimate of $1.07 per s..

Novo Reports Better than Expected Results

Novo Reports Better than Expected Results

Novo Nordisk AS (NYSE: NVO) posted better than expected results for the fiscal year. Shares were up over 8 percent after open on Thursday.The pharmaceutical company reported an 8 percent in operating profits in the first six months of the 2017...

Dish Network misses estimates, loss of subscribers

Dish Network misses estimates, loss of subscribers

Dish Network (NASDAQ:DISH) released its second quarter earnings on Thursday, missing analysts estimates, but the satellite TV operator was able to limit its subscriber losses.The company reported a revenue of $3.64 billion for the quarter ending bac..

Aetna beats Q2 estimates

Aetna beats Q2 estimates

Aetna Inc.’s (NYSE: AET) second quarter earnings report, revealing a 52 percent jump in profit, elevated the stock in early Thursday trading.The nation’s third largest insurer beat on earnings, as analysts had expected on average an EPS ..

Thomson Reuters beats Q2 estimates

Thomson Reuters beats Q2 estimates

Thomson Reuters (NYSE: TRI) reported its second quarter earnings Tuesday morning and reported higher earnings than estimated due to demands for market data.The company reported second-quarter net earnings of $206 million, or 27 cents per share, comp..

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..